1.
|
Phase: Phase IV Type: Treatment Status: Active Age: 1 to 18 Sponsor: Other Protocol IDs: UKALL2003, NCT00222612
|
|
2.
|
Phase: Phase IV Type: Treatment Status: Active Age: 1 to 14 Sponsor: Other Protocol IDs: 2005-000658-56, 20040177, 2004-41-4276, NCT00192673
|
|
3.
|
Phase: Phase IV Type: Treatment Status: Active Age: 14 to 70 Sponsor: Other Protocol IDs: hnslblzlzx2011, NCT01501136
|
|
4.
|
Phase: Phase IV Type: Treatment Status: Active Age: 14 to 70 Sponsor: Other Protocol IDs: hnslblzlzx2011-2, NCT01501149
|
|
5.
|
Phase: Phase IV Type: Treatment Status: Active Age: 15 to 60 Sponsor: Other Protocol IDs: LAL-AR/2011, NCT01540812
|
|
6.
|
Phase: Phase III, Phase II Type: Treatment Status: Active Age: 1 to 17 Sponsor: Other Protocol IDs: CDR0000686545, GPOH-COALL-08-09, EUDRACT-2009-012758-18, EU-21076, NCT01228331
|
|
7.
|
Phase: Phase III Type: Treatment Status: Active Age: 1 to under 30 Sponsor: NCI Protocol IDs: COG-AALL0433, AALL0433, NCT00381680
|
|
8.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 1 and under at diagnosis Sponsor: NCI Protocol IDs: COG-AALL0631, AALL0631, NCT00557193
|
|
9.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and under Sponsor: NCI, Other Protocol IDs: TOTXVI, 5R01CA140729, 5F32CA141762, NCT00549848
|
|
10.
|
Phase: Phase III Type: Treatment Status: Active Age: 1 to 17 Sponsor: Other Protocol IDs: NOPHO ALL2008 PEG Asparaginase, NCT00819351
|
|
11.
|
Phase: Phase III Type: Treatment Status: Active Age: 1 to 18 Sponsor: Other Protocol IDs: CCLG-ALLR3, CCLG-ALLR3, ISCRTN-45724312, EUDRACT-2004-000052-16, EU-20938, NCT00967057
|
|
12.
|
Phase: Phase III Type: Supportive care, Treatment Status: Active Age: 25 to 65 Sponsor: Other Protocol IDs: UCL-08-0167, UCL/08/0167, EU-21009, EUDRACT-2009-012717-22, UCL-UKALL14, MREC-09-H0711-90, NCRI-UCL-08-0167, CRUK-C27995-A9609, NCT01085617
|
|
13.
|
Phase: Phase III Type: Treatment Status: Active Age: Under 18 Sponsor: Other Protocol IDs: AIEOP-BFM ALL 2009, NCT01117441
|
|
14.
|
Phase: Phase III Type: Treatment Status: Active Age: 1 to < 10 Sponsor: NCI Protocol IDs: COG-AALL0932, AALL0932, NCT01190930
|
|
15.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 1 to 30 Sponsor: NCI Protocol IDs: COG-AALL1131, AALL1131, NCT01406756
|
|
16.
|
Phase: Phase III Type: Behavioral study, Treatment Status: Active Age: 1 to under 31 Sponsor: NCI, Other Protocol IDs: CDR0000514500, COG-AALL0434, AALL0434, NCT00408005
|
|
17.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 21 and under Sponsor: Other Protocol IDs: T2009-003, NCT01483690
|
|
18.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and under Sponsor: Other Protocol IDs: ALLR17, NCT00186875
|
|
19.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 to 50 Sponsor: Other Protocol IDs: 06-254, NCT00476190
|
|
20.
|
Phase: Phase II Type: Treatment Status: Active Age: 16 to 39 Sponsor: NCI Protocol IDs: CALGB-10403, CALGB 10403, ECOG C10403, SWOG C10403, NCT00558519
|
|
21.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 18 to 50 Sponsor: NCI Protocol IDs: OSU-08066, OSU 08066, 2008C0112, DFCI-06254, NCT01005758
|
|
22.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 08-007, NCT00837200
|
|
23.
|
Phase: Phase II Type: Treatment Status: Active Age: 1 to 31 Sponsor: NCI Protocol IDs: COG-AALL07P1, AALL07P1, NCT00873093
|
|
24.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 2 to 60 Sponsor: Other Protocol IDs: 2008LS112, 0810M50401, MT2008-29R, UMN-2008LS112, NCT00882206
|
|
25.
|
Phase: Phase II Type: Treatment Status: Active Age: 12 to 40 Sponsor: Other Protocol IDs: 2006-0375, NCT00866749
|